-
Posts
8,082 -
Joined
-
Last visited
-
Days Won
555
MaryO's Achievements
Single Status Update
-
Sosei Group Corporation ("the Company"; TSE: 4565), announces that the first healthy subject has been dosed with a novel small molecule HTL0030310 in a Phase I clinical study, marking the start of a new in-house clinical program targeting endocrine disorders, including Cushing's disease...<br />
<br />
HTL0030310 has been designed to modulate the excess release of hormones from adenomas (benign tumors) of the pituitary gland. Highly elevated plasma levels of pituitary hormones result in a number of serious endocrine disorders, including Cushing's Disease.Read more at https://cushieblog.com/2019/02/20/sosei-heptares-starts-new-clinical-development-program/